<DOC>
	<DOCNO>NCT02097082</DOCNO>
	<brief_summary>An evaluation safety performance STANZA Drug-eluting Resorbable Scaffold ( DRS ) system treatment patient obstructive superficial femoral artery disease .</brief_summary>
	<brief_title>Treatment SFA Lesions With 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold ( DRS ) System</brief_title>
	<detailed_description>The STANZA DRS system comprise controlled release paclitaxel-eluting bioresorbable scaffold delivery system use treatment superficial femoral artery disease .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Intermittent Claudication</mesh_term>
	<criteria>Inclusion Criteria 1 . Age &gt; 18 year . 2 . De novo stenotic lesion ( ) superficial femoral artery locate least 1 cm distal femoral bifurcation &gt; 5 cm joint space knee . 3 . Patient symptomatic intermittent claudication affect least target leg ( Rutherford Class 23 ) . Patients first receive conservative medical management symptom prior study inclusion . The symptoms bilateral . 4 . The study patient inform nature study , agree provision provide write informed consent approve ethic committee respective clinical site . 5 . The study patient agree comply required postprocedure study requirement . Baseline Inclusion Criteria 1 . Reference vessel diameter ( RVD ) 5.0 6.0 mm measure objective measurement online Quantitative Vessel Analysis ( QVA ) . 2 . Target lesion length ≤ 90 mm ; total occlusion length &lt; 40 mm . 3 . Target lesion ≥70 % diameter stenosis . 4 . Angiographic evidence least one runoff vessel ankle/foot without hemodynamically significant stenosis ( &gt; 50 % diameter stenosis ) require treatment within 3 month index procedure . 5 . Procedural access accomplish via contralateral vascular access antegrade access closure device utilized closure occur via manual pressure . 6 . Patent common external iliac : TASC A &amp; B iliac lesion may treat time index procedure ( treatment target lesion ) residual stenosis ≤30 % . Exclusion Criteria 1 . Previous vascular surgery/endovascular treatment target lesion . 2 . Revascularization target vessel within 30 day study procedure . 3 . Critical limb ischemia define Rutherford Becker Category 46 . 4 . Known coagulation disorder intolerance allergy aspirin , clopidogrel ticlopidine , heparin , scaffold component , contrast agent adequately premedicated . 5 . Life expectancy ≤12 month . 6 . Planned procedure necessitate discontinuation antiplatelet medication use conjunction investigational device within 3 month postprocedure . 7 . Inability walk due orthopedic nonvascular complication . 8 . Pregnancy breast feeding patient desire become pregnant . 9 . Nonatherosclerotic lesion ( e.g . vasculitis ) . 10 . Renal insufficiency ( serum creatinine level &gt; 220 µmol/L &gt; 2.5 mg/dl , patient dialysis ) . 11 . Patient medical condition ( ) could affect study assessment may adversely affect safety and/or success study treatment . 12 . Active systemic infection lower limb infection nature . 13 . White Blood Cells ( WBC ) ≤ 3,000 cells/mm3 . 14 . Myocardial infarction within 30 day prior study procedure . 15 . Stroke within 90 day prior study procedure . 16 . Uncontrolled atrial fibrillation . 17 . Currently participate investigational drug another device study . Note : Trials require extend followup product investigational , since become commercially available , consider investigational trial . 18 . Prior use paclitaxeleluting product target limb le 6 month prior index procedure . 19 . Patient know unstable angina . Baseline Exclusion Criteria 1 . Target lesion treatment drug elute balloon . 2 . Target lesion treatment atherectomy , laser , cryoplasty ( use cut score balloon permit prior scaffold implantation ) . 3 . Suspicion evidence subintimal passage guidewire . 4 . Severely calcified lesion ( ) . 5 . Target lesion , base two angiographic orthogonal view , exhibit persistent balloon deformity predilatation nominally size balloon . 6 . Target vessel ( superficial femoral artery ) angiographically significant ( &gt; 50 % diameter stenosis ) lesion locate distally proximally target lesion . 7 . Acute embolic complication follow predilatation . 8 . Target vessel contains acute thrombus . 9 . Aneurysm target vessel coexist clinically significant aneurysmal disease abdominal aorta , iliac popliteal artery . 10 . Intervention infrainguinal artery outside target lesion . 11 . Planned procedure within 30 day index procedure . 12 . Positive pregnancy test females child bear potential .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Peripheral Arterial Disease</keyword>
	<keyword>Intermittent Claudication</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Superficial Femoral Artery</keyword>
</DOC>